Neuble AI
Category: AI in Healthcare
South Korean medical AI startup developing CT-based AI diagnostic solutions for brain diseases including Alzheimer's and stroke, enabling MRI-level brain analysis from accessible CT scans. Neuble AI was founded in 2025. The company is led by Seongjun Ahn (Co-CEO) & Jihoon Kim (Co-CEO). Based in Seoul, South Korea. Team size: 2-10. Total funding raised: $269K. Latest round: Seed. Key investors include FuturePlay.
- Founded
- 2025
- Headquarters
- Seoul, South Korea
- Team size
- 2-10
- Total funding
- $269K
Value proposition
AI-powered brain CT analysis that achieves MRI-level precision for brain volume measurement, enabling faster, cheaper, and more accessible diagnosis of degenerative brain diseases without the long wait times and high costs of MRI.
Products and solutions
BrainCura (AI-powered automated brain volume measurement from CT scans), SynCura (CT-to-MRI image synthesis for acute brain conditions), AngioCura & ReadCura (pipeline products for brain vessel analysis and image reading assistance)
Unique value
World's first AI solution that performs automated brain volume measurement (98 micro-region segmentation, DSC 0.92 accuracy) from CT scans — traditionally only possible via MRI — developed by practicing Gangnam Severance Hospital faculty.
Target customer
University hospitals, general health checkup centers, regional dementia care centers, and global medical institutions
Industries served
Healthcare, Medical Imaging, Neurology, Dementia & Alzheimer's diagnostics, Stroke diagnostics
Technology advantage
Proprietary AI algorithm for CT-based brain segmentation across 98 micro-regions with DSC 0.92 accuracy; CT-to-MRI image synthesis technology; developed on large-scale multi-institutional clinical data; patents filed; founded by practicing clinicians from Gangnam Severance Hospital with direct access to rare high-quality medical data
How they differentiate
Only company globally offering automated brain volume measurement from CT scans (traditionally MRI-only); addresses MRI's accessibility barriers (2-3 month wait times, high cost, contraindications for claustrophobia/metal implants); founded by both a radiologist and a medical physicist combining clinical and technical expertise; SaaS + On-premise hybrid model
Main competitors
Connecteve (코넥티브) - AI X-ray musculoskeletal analysis, Synergy AI (시너지에이아이) - AI organ volume measurement from CT, Coreline Soft (AVIEW NeuroCAD) - AI brain CT hemorrhage detection
Key partnerships
Gangnam Severance Hospital (clinical affiliation of co-founders)
Major milestones
2025-12-31: Company incorporation, 2025: Selected for Preliminary Startup Package Deep Tech (Big Data/AI), 2026-03: Participated in AI FESTA 2025, 2026-07: Raised ₩400M ($269K) seed round from FuturePlay, 2027 H2: Planned commercial launch of BrainCura
Market positioning
Early-stage medical AI startup targeting the rapidly growing dementia diagnosis and treatment market, catalyzed by new Alzheimer's drugs (Lecanemab) requiring patient screening and side-effect monitoring (ARIA). Positioned as a screening and monitoring tool bridging the gap between CT accessibility and MRI-level precision.
Geographic focus
South Korea initially, with plans for US (FDA), Europe (CE), and Southeast Asia expansion
Patents and IP
Patent applications filed (as stated on company website); multi-institutional large-scale clinical data used for model development
About Seongjun Ahn (Co-CEO) & Jihoon Kim (Co-CEO)
Seongjun Ahn: Professor of Radiology at Gangnam Severance Hospital (15+ years clinical experience); Jihoon Kim: Professor of Medical Physics in Radiation Oncology at Gangnam Severance Hospital
Latest news about Neuble AI
More AI in Healthcare companies
Official website: https://neubleai.com